Orna therapeutics establishes strategic collaboration with vertex pharmaceuticals to develop next generation approaches for sickle cell disease (scd) and transfusion-dependent beta thalassemia (tdt)

-- collaboration to leverage orna's differentiated lipid nanoparticle (lnp) delivery solutions for patients with scd and tdt -- -- orna to receive an upfront payment and is eligible to receive potential pre-clinical, clinical, and commercialization milestone payments and royalties -- watertown, mass. , jan. 7, 2025 /prnewswire/ -- orna therapeutics (through its wholly owned subsidiary renagade therapeutics inc.) announced a three-year strategic research collaboration with vertex pharmaceuticals incorporated (nasdaq: vrtx) to utilize orna's novel and proprietary lnp delivery solutions to enhance vertex's efforts in developing next generation gene editing therapies for patients with scd and tdt.
VRTX Ratings Summary
VRTX Quant Ranking